# Enhanced Diclofenac Biodegradation by Bacterial Strains and a Microbial Consortium from Activated Sludge: Toxicity Assessment and Insights into Microbial Community Dynamics

**Authors:** Alba Lara-Moreno, Belen Rodriguez-Morillo, Fernando Madrid, Pedro M. Martin-Sanchez, Jaime Villaverde, Carmen Mejías, Esteban Alonso, Juan Luis Santos, Esmeralda Morillo

PMC · DOI: 10.3390/jox16010024 · Journal of Xenobiotics · 2026-02-02

## TL;DR

This study explores how bacteria and fungi from activated sludge can break down the drug diclofenac, with a focus on their efficiency and the toxicity of byproducts.

## Contribution

The study identifies a microbial consortium and specific bacterial strains capable of completely degrading diclofenac and highlights the importance of assessing metabolite toxicity.

## Key findings

- Pseudomonas sp. CSWD.2 and a microbial consortium achieved 100% diclofenac removal in 21 and 5 days, respectively.
- Three extracellular metabolites were detected, with 4’-OH-DCF and NO2-DCF showing increased toxicity.
- Burkholderia and Talaromyces were the dominant bacteria and fungi in the microbial consortium after bioremediation.

## Abstract

Diclofenac (DCF) is a widely used non-steroidal anti-inflammatory drug whose presence in environmental matrices has led to its classification as an emerging contaminant. Developing effective and sustainable removal strategies is therefore essential. In this study, Pseudomonas aeruginosa CSWD.1, Pseudomonas sp. CSWD.2, and a microbial consortium (MC) were isolated from activated sludge through enrichment cultures with DCF and employed as laboratory models to investigate DCF biodegradation capacity under a biosafety-aware framework. Biodegradation assays supplemented with glucose showed limited removal (45.5%) by CSWD.1, whereas CSWD.2 and the MC achieved complete elimination (100%) of 10 mg L−1 DCF in 21 and 5 days, respectively. Three extracellular metabolites, 4’-hydroxy-diclofenac (4’-OH-DCF), 5-hydroxy-diclofenac (5-OH-DCF), and putative NO2-DCF, were detected, with concentrations varying during degradation. Persistence of 4’-OH-DCF and tentatively identified NO2-DCF after 28 days was potentially associated with increased toxicity relative to the abiotic control. Overall, the results suggest that evaluating metabolites and their toxicity is essential, requiring isolation of additional microorganisms able to degrade 4’-OH-DCF and NO2-DCF to combine with the microorganisms isolated in this study. Metabarcoding analysis of the microbial consortium after bioremediation revealed the dominant bacterial population of Burkholderia (88.9% relative abundance) and a predominant fungal genus Talaromyces (80.1%), indicating that both bacteria and fungi may be associated with DCF transformation. These results provide insights into microbial community dynamics and their potential application in designing effective consortia for DCF bioremediation.

## Linked entities

- **Chemicals:** diclofenac (PubChem CID 3033), 4’-hydroxy-diclofenac (PubChem CID 116545), 5-hydroxy-diclofenac (PubChem CID 3052566)
- **Species:** Pseudomonas aeruginosa (taxon 287), Pseudomonas sp. (taxon 306), Burkholderia (taxon 32008), Talaromyces (taxon 5094)

## Full-text entities

- **Genes:** COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512] {aka COI, MTCO1}, MRM2 (mitochondrial rRNA methyltransferase 2) [NCBI Gene 29960] {aka FJH1, FTSJ2, HEL97, MTDPS17, RRMJ2}, MRM1 (mitochondrial rRNA methyltransferase 1) [NCBI Gene 79922], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}
- **Diseases:** chronic pain (MESH:D059350), MC (MESH:D015163), inflammatory drugs (MESH:D000081015), CSWD.2 (MESH:D020803), CSWD.1 (MESH:C538557), acute and chronic inflammation (MESH:D007249), injury to (MESH:D014947), multidrug (MESH:D018088), Pain (MESH:D010146), Toxicity (MESH:D064420)
- **Chemicals:** CO2 (MESH:D002245), 4-aminophenol (MESH:C026729), DCF (MESH:D004008), 5-hydroxy-diclofenac (MESH:C117715), H2O (MESH:D014867), benzene (MESH:D001554), aspirin (MESH:D001241), hexachlorocyclohexane (MESH:D001556), (NH4)2SO4 (MESH:D000645), carbamazepine (MESH:D002220), arachidonic acid (MESH:D016718), lipids (MESH:D008055), penicillin G (MESH:D010400), catechol (MESH:C034221), ammonium acetate (MESH:C018824), GLU (MESH:D018698), AS (MESH:D001151), ZnSO4 (MESH:D019287), CaCl2 (MESH:D002122), pentachlorophenol (MESH:D010416), ROS (MESH:D017382), CAS (MESH:D002118), polycyclic aromatic hydrocarbon (MESH:D011084), NaOH (MESH:D012972), 4'-hydroxy-diclofenac (MESH:C108036), benzylpenicilloic acid (MESH:C030990), CoCl2 (MESH:C018021), glucose (MESH:D005947), NO (MESH:D009614), ibuprofen (MESH:D007052), NaCl (MESH:D012965), benzo(a)pyrene (MESH:D001564), naproxen (MESH:D009288), homogentisate (MESH:D006713), 4',5-dihydroxydiclofenac (-), MgCl2 (MESH:D015636), penicillin (MESH:D010406), paracetamol (MESH:D000082), CuSO4 (MESH:D019327), Paa (MESH:C037816), ODS (MESH:C024779), nitrogen (MESH:D009584), lactam (MESH:D007769), K2HPO4 (MESH:C013216), orthophosphoric acid (MESH:C030242), prostaglandin (MESH:D011453), benzoic acid (MESH:D019817), toluene (MESH:D014050), phenylacetic acid (MESH:C025136), carbon (MESH:D002244), chlorine (MESH:D002713), agar (MESH:D000362), acetonitrile (MESH:C032159)
- **Species:** Cladosporium (genus) [taxon 5498], Enterococcus faecalis (species) [taxon 1351], Pseudomonas syringae (species) [taxon 317], Parachlamydia (genus) [taxon 83551], Burkholderia sp. AK-5 (species) [taxon 221273], Aliivibrio fischeri (species) [taxon 668], Klebsiella sp. (species) [taxon 576], Mycosphaerella (genus) [taxon 41254], Staphylococcus haemolyticus (species) [taxon 1283], activated sludge metagenome (species) [taxon 942017], Acremonium [taxon 1036747], Fungi (kingdom) [taxon 4751], Daphnia (common water fleas, genus) [taxon 6668], Penicillium (genus) [taxon 5073], Sphingopyxis (genus) [taxon 165697], Legionella (genus) [taxon 445], Stenotrophomonas humi (species) [taxon 405444], Talaromyces (genus) [taxon 5094], Aspergillus luchuensis (species) [taxon 1069201], Debaryomyces hansenii (species) [taxon 4959], Meyerozyma caribbica (species) [taxon 66948], Ochrobactrum (genus) [taxon 528], Enterobacter hormaechei (CDC Enteric Group 75, species) [taxon 158836], Talaromyces gossypii (species) [taxon 28559], Raoultella sp. (species) [taxon 1873496], Alcaligenes faecalis (species) [taxon 511], Rhizobium (genus) [taxon 379], Escherichia coli (E. coli, species) [taxon 562], Malassezia (genus) [taxon 55193], Achromobacter sp. (species) [taxon 134375], Pseudomonas aeruginosa (species) [taxon 287], Chthoniobacter (genus) [taxon 295577], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Rhodococcus (genus) [taxon 1661425], Staphylococcus aureus (species) [taxon 1280], Talaromyces verruculosus (species) [taxon 198730], Labrys (genus) [taxon 2066135], Candida [taxon 1535326], Proteus mirabilis (species) [taxon 584], Homo sapiens (human, species) [taxon 9606], Pseudomonas sp. (species) [taxon 306], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Burkholderia (genus) [taxon 32008], Trichoderma (genus) [taxon 5543], Burkholderia sp. (species) [taxon 36773], Chlorophyta (green algae, phylum) [taxon 3041], Aspergillus niger (species) [taxon 5061]
- **Cell lines:** KB4 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0372)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12921880/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12921880/full.md

## References

129 references — full list in the complete paper: https://tomesphere.com/paper/PMC12921880/full.md

---
Source: https://tomesphere.com/paper/PMC12921880